Document:

Form of Stock Option Grant Agreement

 Exhibit 10.3 
 FORM OF STOCK OPTION AGREEMENT 
 THIS STOCK OPTION AGREEMENT (this
“Agreement”), dated as of as of this [        ] day of [                    ], by and
between Cancer Genetics, Inc., a Delaware corporation (the “Company”), and [                    ] (the “Optionee”). The
Company and the Optionee are sometimes referred to herein individually, as a “Party” and collectively, as the “Parties.” 
 1. Grant of Option. The Company hereby grants an option (the “Option”) to purchase the total number of shares of common stock of the Company (the “Shares”) set forth in the
notice of stock option grant (the “Notice”), at the exercise price per share set forth in the Notice (the “Exercise Price”) subject to the terms and conditions of the Cancer Genetics, Inc. 2008 Stock Option Plan (the
“Plan”) adopted by the Company, which is incorporated in this Agreement by reference. Capitalized terms not defined herein shall have the meaning assigned to them in the Plan. 

2. Designation of Option. This Option is intended to be an Incentive Stock Option only to the extent so designated in the Notice,
and to the extent it is not so designated or to the extent the Option does not qualify as an Incentive Stock Option, it is intended to be a Nonstatutory Stock Option. 
 Notwithstanding the above, if designated as an Incentive Stock Option, in the event that the Shares subject to this Option (and all other Incentive Stock Options granted to the Optionee by the Company or
any Parent or Subsidiary, including under other plans of the Company) that first become exercisable in any calendar year have an aggregate fair market value (determined for each Share as of the date of grant of the option covering such Share) in
excess of $100,000, the Shares in excess of $100,000 shall be treated as subject to a Nonstatutory Stock Option, in accordance with Section 5(c) of the Plan. 
 3. Exercise of Option. This Option shall be exercisable during its term in accordance with the Vesting/Exercise Schedule set out in the Notice and with the provisions of Section 10 of the Plan
as follows: 
 (a) Right to Exercise. 
 (i) This Option may not be exercised for a fraction of a share. 
 (ii) In the
event of the Optionee’s death, disability or other termination of employment, the exercisability of the Option is governed by Section 5 below, subject to the limitations contained in this Section 3. 

(iii) In no event may this Option be exercised after the Expiration Date of the Option as set forth in the Notice. 

 (b) Method of Exercise. 

(i) This Option shall be exercisable by execution and delivery of the exercise notice and restricted stock purchase agreement attached
hereto as Exhibit A (the “Exercise Agreement”) or of any other form of written notice approved for such purpose by the Company which shall state the Optionee’s election to exercise the Option, the number of Shares in respect of which
the Option is being exercised, and such other representations and agreements as to the holder’s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions of the Plan. Such written notice shall be
signed by the Optionee and shall be delivered to the Company by such means as are determined by the Plan Administrator in its discretion to constitute adequate delivery. The written notice shall be accompanied by payment of the Exercise Price. This
Option shall be deemed to be exercised upon receipt by the Company of such written notice accompanied by the Exercise Price. 

(ii) As a condition to the exercise of this Option and as further set forth in Section 11 of the Plan, the Optionee agrees to make
adequate provision for federal, state or other tax withholding obligations, if any, which arise upon the vesting or exercise of the Option, or disposition of Shares, whether by withholding, direct payment to the Company, or otherwise. 

(iii) The Company is not obligated, and will have no liability for failure, to issue or deliver any Shares upon exercise of the Option
unless such issuance or delivery would comply with Applicable Laws, with such compliance determined by the Company in consultation with its legal counsel. This Option may not be exercised (a) until such time as the Plan has been approved by the
stockholders of the Company, or (b) if the issuance of such Shares upon such exercise or the method of payment of consideration for such Shares would constitute a violation of any applicable federal or state securities or other law or
regulation, including any rule under Part 221 of Title 12 of the Code of Federal Regulations as promulgated by the Federal Reserve Board. As a condition to the exercise of this Option, the Company may require the Optionee to make any representation
and warranty to the Company as may be required by Applicable Laws. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to the Optionee on the date on which the Option is exercised with respect to such Shares.

 4. Method of Payment. Payment of the Exercise Price shall be by any of the following, or a combination of the
following, at the election of the Optionee: 
 (a) cash or check or cancellation of indebtedness of the Company to the Optionee;
or 
 (b) by surrender of other shares of Common Stock of the Company that have an aggregate Fair Market Value on the date of
surrender equal to the Exercise Price of the Shares as to which the Option is being exercised. In the case of shares acquired directly or indirectly from the Company, such shares must have been owned by the Optionee for more than six (6) months
on the date of surrender (or such other period of time as is necessary to avoid the Company’s incurring adverse accounting charges). 
 5. Termination of Relationship. Following the date of termination of the Optionee’s Continuous Service Status for any reason (the “Termination Date”), the Optionee may exercise the
Option only as set forth in the Notice and this Section 5. To the extent that the Optionee is not entitled to exercise this Option as of the Termination Date, or if the Optionee does not exercise this

  
 2 

 
Option within the Termination Period set forth in the Notice or the termination periods set forth below, the Option shall terminate in its entirety. In no event, may any Option be exercised after
the Expiration Date of the Option as set forth in the Notice. 
 (a) Termination. In the event of termination of the
Optionee’s Continuous Service Status other than as a result of the Optionee’s disability or death, the Optionee may, to the extent otherwise so entitled at the date of such termination, exercise this Option during the Termination Period
set forth in the Notice. 
 (b) Other Terminations. In connection with any termination other than a termination covered
by Section 5(a), the Optionee may exercise the Option only as described below: 
 (i) Termination upon Disability of
Optionee. In the event of termination of the Optionee’s Continuous Service Status as a result of the Optionee’s disability (within the meaning of Section 22(e)(3) of the Code), the Optionee may, but only within one (1) year
from the Termination Date, exercise this Option to the extent the Optionee was entitled to exercise it as of such Termination Date. 
 (ii) Death of Optionee. In the event of the death of the Optionee (a) during the term of this Option and while an Employee or Consultant of the Company and having been in Continuous Service
Status since the date of grant of the Option, or (b) within thirty (30) days after the Optionee’s Termination Date, the Option may be exercised at any time within six months following the date of death by the Optionee’s estate or
by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent the Optionee was entitled to exercise the Option as of the Termination Date. 

6. Non-Transferability of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of
descent or distribution and may be exercised during the lifetime of the Optionee only by him or her. The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 

7. Tax Consequences. Below is a brief summary as of the date the Plan was adopted of certain of the federal tax consequences of
exercise of this Option and disposition of the Shares under the laws in effect as of the Date of Grant. THIS SUMMARY IS INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. THE OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING
THIS OPTION OR DISPOSING OF THE SHARES. 
 (a) Incentive Stock Option. 

(i) Tax Treatment upon Exercise and Sale of Shares. If this Option qualifies as an Incentive Stock Option, there will be no
regular federal income tax liability upon the exercise of the Option, although the excess, if any, of the fair market value of the Shares on the date of exercise over the Exercise Price will be treated as an adjustment to the alternative minimum tax
for federal tax purposes and may subject the Optionee to the alternative minimum tax in the year of exercise. If Shares issued upon exercise of an Incentive Stock Option are held for at least one year after exercise and are disposed of no sooner
than two years after the Option grant date, any gain realized on disposition of the Shares will be treated as long-term capital gain for federal income tax purposes. If Shares issued upon exercise of an Incentive Stock Option are disposed of within
such 

  
 3 

 
one-year period or within two years after the Option grant date, any gain realized on such disposition will be treated as compensation income (taxable at ordinary income rates) to the extent of
the difference between the Exercise Price and the lesser of (i) the fair market value of the Shares on the date of exercise, or (ii) the sale price of the Shares. 
 (ii) Notice of Disqualifying Dispositions. With respect to any Shares issued upon exercise of an Incentive Stock Option, if the Optionee sells or otherwise disposes of such Shares on or before the
later of (i) the date two years after the Option grant date, or (ii) the date one year after the date of exercise, the Optionee shall immediately notify the Company in writing of such disposition. The Optionee acknowledges and agrees that
he or she may be subject to income and other employment tax withholding by the Company on the compensation income recognized by the Optionee from the early disposition by payment in cash or out of the current earnings paid to the Optionee.

 (b) Nonstatutory Stock Option. If this Option does not qualify as an Incentive Stock Option, there may be a regular
federal, state or local income tax liability upon the exercise of the Option. The Optionee will be treated as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if any, of the fair market value of the
Shares on the date of exercise over the Exercise Price. If the Optionee is an Employee, the Company will be required to withhold from the Optionee’s compensation or collect from the Optionee and pay to the applicable taxing authorities an
amount equal to a percentage of this compensation income at the time of exercise. If Shares issued upon exercise of a Nonstatutory Stock Option are held for at least one year, any gain realized on disposition of the Shares will be treated as
long-term capital gain for federal income tax purposes. 
 8. Effect of Agreement; Entire Agreement. The Optionee
acknowledges receipt of a copy of the Plan and represents that the Optionee is familiar with the terms and provisions thereof (and has had an opportunity to consult counsel regarding the Option terms), and hereby accepts this Option and agrees to be
bound by its contractual terms as set forth herein and in the Plan. The Optionee hereby agrees to accept as binding, conclusive and final all decisions and interpretations of the Plan Administrator regarding any questions relating to the Option. In
the event of a conflict between the terms and provisions of the Plan and the terms and provisions of the Notice and this Agreement, the Plan terms and provisions shall prevail. The Option, including the Plan, constitutes the entire agreement between
the Optionee and the Company on the subject matter hereof and supersedes all proposals, written or oral, and all other communications between the parties relating to such subject matter. 

9. Miscellaneous. 
 (a) Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be governed, construed and interpreted in accordance with the
laws of the State of Delaware, without giving effect to principles of conflicts of law. 
 (b) Enforcement of Rights. No
modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the Parties. The failure by either Party to enforce any rights under this Agreement shall not be
construed as a waiver of any rights of such Party. 

  
 4 

 (c) Severability. If one or more provisions of this Agreement are held to be
unenforceable under Applicable Laws, the Parties agree to renegotiate such provision in good faith. In the event that the Parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be
excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded, and (iii) the balance of the Agreement shall be enforceable in accordance with its terms. 

(d) Construction. This Agreement is the result of negotiations between and has been reviewed by each of the Parties and their
respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the Parties, and no ambiguity shall be construed in favor of or against any one of the Parties. 

(e) Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when delivered
personally or sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such Party’s address or fax number as set forth below
or as subsequently modified by written notice: 
 if to the Company to: 

Cancer Genetics, Inc. 
 Meadows Office Complex 
 201 Route 17 North, 2nd Floor 

Rutherford, New Jersey 07070 
 Attention: President 
 with a copy to: 

Lavelle & Finn, LLP 
 29 British American Blvd. 
 Latham, New York 12110 

Attention: Keith M. Goldstein, Esq. 
 if to the Optionee to: 

[                    ] 

(f) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument. 
 [Signature Page to Follow] 

  
 5 

 IN WITNESS WHEREOF, each Party has executed, or caused to be executed by a duly
authorized individual, this Agreement as of the date first set forth above. 
  

					
		 	CANCER GENETICS, INC.
		
	By:	 	  

		 	Name:	 	[                    ]
		 	Title:	 	[                    ]
		
		 	OPTIONEE
		
		 	  

		 	[                    ]

  
 6Form of Exercise Notice and Restricted Stock Purchase Agreement

 Exhibit 10.4 
 FORM OF EXERCISE NOTICE AND RESTRICTED 
 STOCK PURCHASE AGREEMENT

 THIS EXERCISE NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of
this        day of            ,        , by and between Cancer Genetics, Inc., a Delaware corporation (the
“Company”), and                    (the “Purchaser”). The Company and the Purchaser are sometimes referred to herein
individually, as a “Party” and collectively, as the “Parties.” 
 1. Exercise of Option. Subject to
the terms and conditions hereof, the Purchaser hereby elects to exercise his or her option to purchase            shares of common stock of the Company (the “Shares”) under and
pursuant to the Plan and the stock option agreement, by and between the Company and the Purchaser, dated                     (the “Option
Agreement”). The purchase price for the Shares shall be $        per share for a total purchase price of $        . The term “Shares” refers to the
purchased shares and all securities received in replacement of the shares or as stock dividends or splits, all securities received in replacement of the shares in a recapitalization, merger, reorganization, exchange or the like, and all new,
substituted or additional securities or other properties to which the Purchaser is entitled by reason of the Purchaser’s ownership of the Shares. Capitalized terms not defined herein shall have the meaning assigned to them in the Cancer
Genetics, Inc. 2008 Stock Option Plan (the “Plan”). 
 2. Time and Place of Exercise. The purchase and sale of
the Shares under this Agreement shall occur at the principal office of the Company simultaneously with the execution and delivery of this Agreement in accordance with the provisions of Section 3(b) of the Option Agreement. On such date, the
Company will deliver to the Purchaser a certificate representing the Shares to be purchased by the Purchaser (which shall be issued in the Purchaser’s name) against payment of the exercise price therefor by the Purchaser by (a) check made
payable to the Company, (b) cancellation of indebtedness of the Company to the Purchaser, (c) delivery of shares of the common stock of the Company in accordance with Section 4 of the Option Agreement, or (d) by a combination of
the foregoing. 
 3. Limitations on Transfer. 
 (a) In addition to any other limitation on transfer created by applicable securities laws, the Purchaser shall not assign, encumber or dispose of any interest in the Shares except in compliance with the
provisions below and applicable securities laws. 
 (b) Right of First Refusal. Before any Shares held by the Purchaser
or any transferee of the Purchaser (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignce(s) shall have a right of
first refusal to purchase the Shares on the terms and conditions set forth in this Section 3(b) (the “Right of First Refusal”). 
 (i) Notice of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”) stating: (A) the Holder’s bona fide intention to sell or
otherwise transfer such Shares; (B) the name of each proposed purchaser or other transferee (“Proposed Transferee”); (C) the number of Shares to be transferred to each Proposed Transferee; and (D) the terms and conditions of
each proposed sale or transfer. The Holder shall offer the Shares 

 
at the same price (the “Offered Price”) and upon the same terms (or terms as similar as reasonably possible) to the Company or its assignee(s) (the “First Inside Offer”)

 (ii) Exercise of Right of First Refusal. 
 (A) At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, or a portion, of the Shares
proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with Section 3(b)(iii). 
 (B) If the Company does not acquire all of the Shares pursuant to Section 3(b)(ii)(A), or acquires only a portion of the Shares, the Purchaser shall thereupon deliver to each of the other
stockholders of the Company (“Stockholders”) a written offer irrevocable for fifteen (15) days to sell to such Stockholders for a price determined in accordance with Section 3(b)(iii), all, or a portion, of the Shares which the
Company has not elected to purchase in the First Inside Offer (hereinafter referred to as the “Second Inside Offer”), on the same terms and conditions as the First Inside Offer. The Stockholders shall have the right to accept the Second
Inside Offer on at least a pro rata basis in accordance with the number of shares of capital stock owned by each of them in relation to the number of shares of capital stock owned by Stockholders other than the Selling Holder, calculated on a fully
diluted basis. Each exercising Stockholder shall give written notice to the Selling Holder and to the Company stating the quantity of shares which such Stockholder desires to purchase (which quantity may exceed the number of shares such Stockholder
would be entitled to purchase on a pro rata basis as provided above in this paragraph if all Stockholders exercised this right). If the total number of shares specified in such Stockholders’ notices exceed the number of shares offered in the
Second Inside Offer, each exercising Stockholder shall have the right to purchase such portion of the shares offered in the Second Inside Offer on a pro rata basis with all other exercising Stockholders determined as provided above in this
paragraph, up to the number of shares specified in its notice. The shares not so purchased shall be allocated on a pro rata basis determined as provided above in this paragraph among the exercising Stockholders electing to purchase more than their
pro rata portions up to the number of shares specified in each exercising Stockholders’ notice to the Selling Holder. 

(iii) Purchase Price. The purchase price (“Right of First Refusal Purchase Price”) for the Shares purchased by the
Company or its assignee(s) or Stockholders under this Section 3(b) shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the board
of directors of the Company in good faith. 
 (iv) Payment. Payment of the Right of First Refusal Purchase Price shall
be made, at the option of the Company or its assignee(s) and/or the Stockholders, in cash (by check), by cancellation of all or a portion of any outstanding indebtedness, or by any combination thereof within thirty (30) days after receipt of
the notices or in the manner and at the times set forth in the notices. 
 (v) Holder’s Right to Transfer. If all
of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company, its assignee(s) and/or the Stockholders as provided in this Section 3(b), then the Holder may sell or otherwise transfer
such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided 

 
that such sale or other transfer is consummated within sixty (60) days after the date of the Notice and provided further that any such sale or other transfer is effected in accordance with
any applicable securities laws and the Proposed Transferee agrees in writing that the provisions of this Section 3 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, or if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Notice shall be given to the Company, and the Company and/or its
assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 
 (vi) Exceptions from the Right of First Refusal. Notwithstanding the foregoing, the Purchaser may transfer all, or any portion, of the Shares, without regard to the limitations set forth in this
Section 3(b) in each of the following cases: (A) to the Company; (B) in a transaction in which the aggregate amount of consideration for the Shares is less than Five Thousand Dollars ($5,000.00); (C) if prior to such sale, the
Purchaser held less than five percent (5%) of the outstanding capital stock of the Company; (D) as part of a registered public offering of the Company’s securities; and (E) either during the Purchaser’s lifetime or on death
by will or intestacy to a custodian or trustee for the account of the Purchaser or the Purchaser’s siblings, ancestors, descendants or spouse (in each case, a “Permitted Transfer”); provided, however, that, in the case
of a Permitted Transfer pursuant to this Section 3(b)(vi), a transferee shall receive and hold such Shares subject to the provisions of this Agreement and there shall be no further transfer of such Shares except in accordance herewith.
Notwithstanding any provision pursuant to this Section 3 to the contrary, the Purchaser shall not transfer pursuant to this Section 3(b)(vi)(E), without the express written consent of the board of directors of the Company, in any calendar
year, greater than twenty-five percent (25%) of the Shares held on the date first set forth above. 
 (c) Involuntary
Transfer. 
 (i) Company’s Right to Purchase upon Involuntary Transfer. In the event, at any time after the date
of this Agreement, of any transfer by operation of law or other involuntary transfer (including divorce or death, but excluding in the event of death a transfer as set forth in Section 3(b)(vi)(E)) of all or a portion of the Shares by the
record holder thereof, the Company shall have the right to purchase all of the Shares transferred at the greater of the purchase price paid by the Purchaser pursuant to this Agreement or the fair market value of the Shares on the date of transfer as
determined by Section 3 (c)(ii), below. Upon such a transfer, the person acquiring the Shares shall promptly notify the secretary of the Company of such transfer. The right to purchase such Shares shall be provided to the Company for a period
of thirty (30) days following receipt by the Company of written notice by the person acquiring the Shares. 
 (ii)
Price for Involuntary Transfer. With respect to any stock to be transferred pursuant to Section 3(c)(i), the price per Share shall be a price set by the board of directors of the Company that will reflect the current value of the stock
in terms of present earnings and future prospects of the Company. The Company shall notify the Purchaser or his or her executor of the price so determined within thirty (30) days after receipt by it of written notice of the transfer or proposed
transfer of Shares; provided, however, if the Purchaser does not agree with the valuation as determined by the board of directors of the Company, the Purchaser shall be entitled to have the valuation determined by an independent
appraiser to be mutually agreed upon by the Company and the Purchaser and whose fees shall be borne equally by the Company and the Purchaser. 

 (d) Assignment. The right of the Company to purchase any part of the Shares may be
assigned in whole or in part to any stockholder or stockholders of the Company or other persons or organizations. 
 (e)
Restrictions Binding on Transferees. All transferees of Shares or any interest therein will receive and hold such Shares or interest subject to the provisions of this Agreement. 

(f) Termination of Rights. The Right of First Refusal and the Company’s right to repurchase the Shares in the event of an
involuntary transfer pursuant to Section 3(c) above shall terminate upon the first sale of common stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange
Commission under the Securities Act of 1933, as amended (the “Securities Act”). 
 (g) Market Stand-off
Agreement. In connection with an initial public offering of the Company’s securities and upon request of the Company or the underwriters managing such offering of the Company’s securities, the Purchaser agrees not to sell, make any
short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may
be, for such period of time (not to exceed one hundred eighty days (180) days) from the effective date of such registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as
may be requested by the underwriters at the time of the Company’s initial public offering. 
 4. Investment and Taxation
Representations. In connection with the purchase of the Shares, the Purchaser represents to the Company the following: 

(a) Investment Intent: Capacity to Protect Interests. The Purchaser is purchasing the Shares solely for Purchaser’s own
account for investment and not with a view to, or for sale in connection with, any distribution of the Shares or any portion thereof and not with any present intention of selling, offering to sell or otherwise disposing of or distributing the Shares
or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act. The Purchaser also represents that the entire legal and beneficial interests of the Shares is being purchased, and will be held,
for the Purchaser’s account only, and neither in whole nor in part for any other person. The Purchaser either (a) has a preexisting business or personal relationship with the Company or any of its officers, directors or controlling
persons, or (b) by reason of Purchaser’s business or financial experience, or the business or financial experience of Purchaser’s professional advisors who are unaffiliated with and who are not compensated by the Company or any
affiliate or selling agent of the Company, directly or indirectly, could be reasonably assumed to have the capacity to evaluate the merits and risks of an investment in the Company and to protect Purchaser’s own interests in connection with
this transaction. 
 (b) Residence. The Purchaser’s principal residence is within the State set forth in
Section 6(e). 
 (c) Information Concerning Company. The Purchaser has heretofore discussed the Company and its
plans, operations and financial condition with the Company’s officers and has heretofore received all such information as the Purchaser has deemed necessary and appropriate to enable the Purchaser to evaluate the financial risk inherent in
making an investment in the Shares, 

 
and the Purchaser has received satisfactory and complete information concerning the business and financial condition of the Company in response to all inquiries in respect thereof. 

(d) Economic Risk. The Purchaser realizes that the purchase of the Shares will be a highly speculative investment and involves a
high degree of risk, and the Purchaser is able, without impairing the Purchaser’s financial condition, to hold the Shares for an indefinite period of time and suffer a complete loss on the Purchaser’s investment. 

(e) Restricted Securities. The Purchaser understands and acknowledges that: 

(i) the sale of the Shares has not been registered under the Securities Act, the Shares must be held indefinitely unless subsequently
registered under the Securities Act or an exemption from such registration is available and the Company is under no obligation to register the Shares. 
 (ii) the share certificate representing the Shares will bear the legends specified in Section 5 hereof; and 
 (iii) the Company will make a notation in its records of the aforementioned restrictions on transfer and legends. 
 5. Restrictive Legends and Stop-Transfer Orders. 
 (a) Legends. The
certificate or certificates representing the Shares shall bear the following legends (as well as any legends required by applicable state and federal corporate and securities laws): 

 

	 	(i)	“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

 (ii) “THE SHARES REPRESENTED
BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE PURCHASER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.” 

	 	(iii)	Any legend required to be placed thereon by the securities laws of any state. 

 (b) Stop-Transfer Notices. The Purchaser agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer”
instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. 
 (c) Refusal to Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this
Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

(d) Removal of Legend. When all of the following events have occurred, the Shares then held by the Purchaser will no longer be
subject to the legend referred to in Section 5(a)(ii): (i) the termination of the Right of First Refusal; and (ii) the expiration or termination of the market standoff provisions of Section 3(g) (and of any agreement entered
pursuant to Section 3(g). After such time, and upon the Purchaser’s request, a new certificate or certificates representing the Shares not repurchased shall be issued without the legend referred to in Section 5(a)(ii), and delivered
to the Purchaser. 
 6. Miscellaneous. 
 (a) Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be governed, construed and interpreted in accordance with the
laws of the State of Delaware, without giving effect to principles of conflicts of law. 
 (b) Entire Agreement; Enforcement
of Rights. This Agreement sets forth the entire agreement and understanding of the Parties relating to the subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement, nor any waiver of
any rights under this Agreement, shall be effective unless in writing signed by the Parties. The failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such Party. 

(c) Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the Parties agree
to renegotiate such provision in good faith. In the event that the Parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of
the Agreement shall be interpreted as if such provision were so excluded, and (iii) the balance of the Agreement shall be enforceable in accordance with its terms. 
 (d) Construction. This Agreement is the result of negotiations between and has been reviewed by each of the Parties and their respective counsel, if any; accordingly, this Agreement shall be deemed
to be the product of all of the Parties, and no ambiguity shall be construed in favor of or against any one of the Parties. 

 (e) Notices. Any notice required or permitted by this Agreement shall be in writing
and shall be deemed sufficient when delivered personally or sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such
Party’s address or fax number as set forth below or as subsequently modified by written notice: 
  

					
		 	if to the Company to:
		 	  
 Cancer Genetics, Inc.

Meadows Office Complex
 201 Route 17 North,
2nd Floor

Rutherford, New Jersey 07070
 Attention:
President
  
 with a copy to:

		 	  
 Lavelle & Finn, LLP

29 British American Blvd.
 Latham, New York
12110
 Attention: Keith M. Goldstein, Esq.

 

		 	  
 if to the Purchaser to:

		 	  
	 	
		 	  
	 	
		 	  
	 	

 (f) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original and all of which together shall constitute one instrument. 
 (g) Successors and Assigns. The rights and
benefits of this Agreement shall [ILLEGIBLE] to the benefit of, and be enforceable by the Company and its successors and assigns. The rights and obligations of the Purchaser under this Agreement may only be assigned with the prior written consent of
the Company. 
 [Signature Page to Follow] 

 IN WITNESS WHEREOF, each Party has executed, or caused to be executed by a duly
authorized individual, this Agreement as of the date first set forth above. 
  

			
		 	CANCER GENETICS, INC.
		
	By:	 	  

		 	Name:
		 	Title:
		
		 	PURCHASER
		
		 	  

		 	[Insert Name of Purchaser]

 RECEIPT 
 Cancer Genetics, Inc. hereby acknowledges receipt of [Purchase Price] from [Purchaser] in full payment of the purchase price [Number of Securities] shares of
Common Stock of Cancer Genetics, Inc. represented by Certificate No.             . 

Dated:                     

 

			
		 	CANCER GENETICS, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 RECEIPT AND CONSENT 

The undersigned hereby acknowledges receipt of Certificate No.            
for [Number of Securities] shares of common stock of Cancer Genetics, Inc. (the “Company”). 
  

							
	 Dated:
	 		 		 	
				
		 		 		 	  

		 		 		 	[Purchaser]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]